Macaques immunized with HLA-DR are protected from challenge with simian immunodeficiency virus
- PMID: 7707540
- PMCID: PMC189013
- DOI: 10.1128/JVI.69.5.3117-3124.1995
Macaques immunized with HLA-DR are protected from challenge with simian immunodeficiency virus
Abstract
Macaques immunized with uninfected human cells have been shown to be protected from challenge with simian immunodeficiency virus (SIV) propagated in human cells. To identify the potential antigens involved in this protection, macaques were immunized with uninfected human cells, sucrose density gradient-purified culture fluid from uninfected human cells (mock virus), beta-2 microglobulin (beta 2M), immunoaffinity-purified HLA class I and class II proteins from these human cells, and adjuvant. Although all macaques immunized with beta 2M and HLA class I developed high antibody titers to beta 2M, these animals were not protected from a subsequent challenge with infectious SIV grown in human cells. In contrast, the macaques immunized with class II protein (HLA-DR) and mock virus developed antibodies to class II protein and were protected from the intravenous infectious virus challenge. The class II protein- and mock virus-immunized animals which were protected from challenge were given boosters of the appropriate antigen and challenged with the same SIV propagated in macaque cells. All animals became infected, indicating that the protection seen with human class II protein did not extend to protection from infection with SIV containing macaque class II proteins. Since the virus released from SIV-infected macaque cells would contain macaque class II proteins, our results suggest that the initial SIV infected was completely prevented. In addition, the lack of protection from challenge with SIV propagated in macaque cells provided strong evidence that the protection was due to an immune response to the cellular proteins and not to epitopes cross-reactive between class II proteins and the viral proteins, since the identical virus proteins were present in both challenge stocks. These results are the first demonstration that immunization with a purified cellular protein can protect from virus infection.
Similar articles
-
Immunization with recombinant HLA classes I and II, HIV-1 gp140, and SIV p27 elicits protection against heterologous SHIV infection in rhesus macaques.J Virol. 2011 Jul;85(13):6442-52. doi: 10.1128/JVI.00129-11. Epub 2011 Apr 13. J Virol. 2011. PMID: 21490092 Free PMC article.
-
Antibodies to human and non-human primate cellular and culture medium components in macaques vaccinated with the simian immunodeficiency virus.Immunology. 1994 Oct;83(2):213-20. Immunology. 1994. PMID: 7835937 Free PMC article.
-
ALVAC-SIV-gag-pol-env-based vaccination and macaque major histocompatibility complex class I (A*01) delay simian immunodeficiency virus SIVmac-induced immunodeficiency.J Virol. 2002 Jan;76(1):292-302. doi: 10.1128/jvi.76.1.292-302.2002. J Virol. 2002. PMID: 11739694 Free PMC article.
-
A 30-year journey of trial and error towards a tolerogenic AIDS vaccine.Arch Virol. 2018 Aug;163(8):2025-2031. doi: 10.1007/s00705-018-3936-1. Epub 2018 Jul 24. Arch Virol. 2018. PMID: 30043201 Free PMC article. Review.
-
Simian and feline immunodeficiency viruses: animal lentivirus models for evaluation of AIDS vaccines and antiviral agents.Antiviral Res. 1991 May;15(4):267-86. doi: 10.1016/0166-3542(91)90009-g. Antiviral Res. 1991. PMID: 1659310 Review.
Cited by
-
AIDS vaccine: new ideas from old approaches.J R Soc Med. 2003 Jul;96(7):347-8. doi: 10.1177/014107680309600710. J R Soc Med. 2003. PMID: 12835449 Free PMC article. Review. No abstract available.
-
Immunization with recombinant HLA classes I and II, HIV-1 gp140, and SIV p27 elicits protection against heterologous SHIV infection in rhesus macaques.J Virol. 2011 Jul;85(13):6442-52. doi: 10.1128/JVI.00129-11. Epub 2011 Apr 13. J Virol. 2011. PMID: 21490092 Free PMC article.
-
Contribution of virion ICAM-1 to human immunodeficiency virus infectivity and sensitivity to neutralization.J Virol. 1997 Jun;71(6):4847-51. doi: 10.1128/JVI.71.6.4847-4851.1997. J Virol. 1997. PMID: 9151884 Free PMC article.
-
Alloimmunity to Class 2 Human Leucocyte Antigens May Reduce HIV-1 Acquisition - A Nested Case-Control Study in HIV-1 Serodiscordant Couples.Front Immunol. 2022 Mar 24;13:813412. doi: 10.3389/fimmu.2022.813412. eCollection 2022. Front Immunol. 2022. PMID: 35401581 Free PMC article.
-
Vaccine protection by a triple deletion mutant of simian immunodeficiency virus.J Virol. 1996 Jun;70(6):3724-33. doi: 10.1128/JVI.70.6.3724-3733.1996. J Virol. 1996. PMID: 8648707 Free PMC article.
References
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials